We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+14.47%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$547M
AUM Growth
+$108M
Cap. Flow
+$78.2M
Cap. Flow %
14.3%
Top 10 Hldgs %
78.46%
Holding
36
New
6
Increased
6
Reduced
2
Closed
10

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$64.4M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$24.7M
3
ESPR
Esperion Therapeutics
ESPR
+$16.2M
4
WVE icon
Wave Life Sciences
WVE
+$16M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$12M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$41.2M
2
PBYI icon
Puma Biotechnology
PBYI
+$12M
3
ZGNX
Zogenix, Inc.
ZGNX
+$7.01M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$6.22M
5
SBBP
Strongbridge Biopharma plc.
SBBP
+$5.91M

Sector Composition

Rank Sector Weight
1 Healthcare 93.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVXS
1
DELISTED
AveXis, Inc. Common Stock
AVXS
$91.3M 16.69%
825,000
+25,000
+3% +$2.51M
ODT
2
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$68.2M 12.46%
+2,726,938
New +$64.4M
ONC
3
BeOne Medicines Ltd
ONC
$32.8B
$58.6M 10.72%
600,000
– –
ESPR
4
DELISTED
Esperion Therapeutics
ESPR
$52.7M 9.63%
800,000
+300,000
+60% +$16.2M
MGNX icon
5
MacroGenics
MGNX
$235M
$41.8M 7.64%
2,200,000
– –
PTCT icon
6
PTC Therapeutics
PTCT
$5.64B
$29.2M 5.34%
1,750,000
+500,000
+40% +$8.46M
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$25M 4.58%
1,372,510
+334,516
+32% +$5.19M
IONS icon
8
Ionis Pharmaceuticals
IONS
$8.6B
$22.6M 4.14%
+450,000
New +$24.7M
MDCO
9
DELISTED
Medicines Co
MDCO
$20.5M 3.75%
750,000
-150,000
-17% -$4.62M
WVE icon
10
Wave Life Sciences
WVE
$1.09B
$19.3M 3.53%
+550,000
New +$16M
BPMC
11
DELISTED
Blueprint Medicines
BPMC
$18.9M 3.45%
250,000
– –
KURA icon
12
Kura Oncology
KURA
$800M
$12.9M 2.36%
844,789
– –
GTHX
13
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$12.5M 2.28%
629,179
– –
RIGL icon
14
Rigel Pharmaceuticals
RIGL
$681M
$12.2M 2.23%
+314,000
New +$12M
CNCE
15
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$10.3M 1.89%
+400,000
New +$8.05M
CBAY
16
DELISTED
Cymabay Therapeutics
CBAY
$9.32M 1.7%
1,012,986
– –
LJPC
17
DELISTED
La Jolla Pharmaceutical Company
LJPC
$8.61M 1.57%
267,500
– –
ONCT
18
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$7.18M 1.31%
4,038
– –
ARDM
19
DELISTED
Aradigm Corp Common Stock
ARDM
$6.7M 1.22%
1,000,000
+500,000
+100% +$2.2M
VIRX
20
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$4.89M 0.89%
37,857
+8,571
+29% +$803K
BLPH
21
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$4.79M 0.88%
123,810
– –
NGNE icon
22
Neurogene
NGNE
$656M
$3.67M 0.67%
15,625
– –
RCKT icon
23
Rocket Pharmaceuticals
RCKT
$340M
$2.61M 0.48%
+250,000
New +$2.48M
RGLS
24
DELISTED
Regulus Therapeutics
RGLS
$2.29M 0.42%
18,315
– –
SNDX icon
25
Syndax Pharmaceuticals
SNDX
$1.69B
$876K 0.16%
100,000
– –
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2017 Portfolio in Review

As of Q4 2017, Boxer Capital held 36 positions worth $547M, up 25% from $439M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Boxer Capital deployed $78.2M of net new capital in Q4 2017, opening 6 new positions and adding to 6 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 2,726,938 shares worth $68.2M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier.

On the sell side, the largest reduction was Medicines Co, an estimated $4.62M trimmed.

  • Boxer Capital's largest Q4 2017 buy was Odonate Therapeutics, Inc. Common Stock: 2,726,938 shares worth $68.2M.
  • Boxer Capital added most to Esperion Therapeutics in Q4 2017, an estimated $16.2M increase.
  • Boxer Capital's biggest Q4 2017 reduction was Medicines Co, cutting an estimated $4.62M.
  • Boxer Capital fully exited Clovis Oncology, Inc. in Q4 2017, selling an estimated $41.2M.
  • Boxer Capital's ten largest holdings make up 78% of its $547M portfolio in Q4 2017.
  • Boxer Capital opened 6 new positions and closed 10 in Q4 2017.
  • Boxer Capital's portfolio value rose 25% quarter-over-quarter to $547M.

Based on Boxer Capital's 13F filing for Q4 2017, filed 14 Feb 2018.